Top Health Tech Companies in Hyderabad (67)

Investor Backing & Capital Strength: A $90M Series C in May 2025—corroborated by trade press—was secured to expand the AI-driven platform and scale operations. Additional equity raised in 2024 and total capital around $200M signal strong investor support for growth.

Product Line Growth: In September 2025 the company launched a Payment Integrity suite and acquired ZignaAI, extending beyond utilization management into claims/payment accuracy. Subsequent 2026 updates expanded the platform into appeals, care management, claims operations, and quality.

Market Expansion: Payer materials indicate Cohere Health reviews Humana prior authorization requests nationwide, with HealthPartners documents in 2025–2026 showing adoption beyond Humana. Company-reported operating scale (600k+ providers, millions of requests) and added plan wins through 2026 suggest a broader payer footprint.

Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.

Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.

Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.

Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.

Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.

Cost & Operational Efficiency: Cost-savings efforts are positioned as a concrete lever to support improved earnings and fund growth priorities, with an enterprise-wide program targeting substantial savings over multiple years. Guidance frames these actions as part of a broader move toward sustained revenue and earnings improvement beginning in 2026.

Resilient & Sustainable Growth: Growth is presented as re-emerging, with management guiding to a return to modest year-over-year revenue expansion in 2026 after a softer 2025. Improving quarterly trends exiting 2025 and a baseline of modest operational growth excluding divestitures support a narrative of stabilization.

Strong Market Position & Advantage: Scale and global reach are repeatedly highlighted as a stabilizing advantage, with broad geographic coverage and a large portfolio supporting access, supply reach, and competitive standing in off-patent medicines. The strategic shift toward complex generics and specialty brands is framed as reinforcing the company’s long-term positioning against pricing pressures.

Strong Revenue Growth: Revenue accelerated to the fastest annual pace in a decade in FY2026, with momentum evident into the fourth quarter. Management’s outlook points to continued upper single‑digit organic expansion in the coming year.

Healthy Cash Flow: Strong free cash flow and a long-running pattern of dividend increases indicate durable cash generation. Recent dividend actions and ongoing cash returns underscore capacity to fund investment and tuck‑in M&A.

Strong Market Position & Advantage: Scale leadership at the top of global medtech by revenue, with breadth across Cardiovascular, Neuroscience, and Medical Surgical, supports resilience. Category strength in areas like cardiac pacing and ablation provides commercial leverage for new launches.

Strong Market Position & Advantage: GHX is depicted as operating healthcare’s largest cloud-based trading network with extensive provider–supplier connectivity across North America and Europe, with leadership most often cited in exchange connectivity, procure-to-pay automation, and analytics. Industry recognitions and programs tied to high volumes of automated and “perfect order” transactions underscore significant network scale and stickiness.

Innovation-Driven Growth: Recent launches such as an orchestration platform and ResiliencyAI highlight active investment in data, workflow automation, and disruption management beyond basic transaction exchange. The 2025–2026 announcement cadence suggests a push toward networked decisioning that can expand use cases and wallet share.

Investor Backing & Capital Strength: A new majority stake by Veritas Capital, with Temasek remaining involved, is framed as enabling the next stage of growth through further product investment and potential M&A. Ownership history alongside ongoing releases indicates sustained capital support for expansion.

Strong Market Position & Advantage: Analyst and client recognitions position EPAM as a leader in digital engineering and AI-enabled transformation, including multiple IDC MarketScape leadership placements and a Gartner recognition for custom software development. Independent coverage likewise describes the firm as a leading provider in these segments, reinforcing a durable competitive footing.

Resilient & Sustainable Growth: Revenue continues to expand year over year in recent quarters and on a trailing-twelve-month basis, and management still guides to growth for the current year despite a tougher backdrop. The pace has moderated compared with the prior year, but the trajectory remains positive.

Innovation-Driven Growth: The company is leaning into AI-native services and is identified as a leader in AI transformation engineering alongside strengths in data modernization and software engineering. This innovation-led mix is presented as a key engine for future expansion.

Strong Revenue Growth: Revenue is described as rising across recent years and quarters, supported by new long‑term contracts, acquisitions, and expanding client deployments. Technology‑enabled offerings and growing demand for outsourced RCM are cited as tailwinds.

Strong Market Position & Advantage: The company is presented as a category leader with an extensive client base that includes a large share of top U.S. health systems and repeated top rankings in ambulatory services. Its end‑to‑end platform and scale are highlighted as differentiators.

Investor Backing & Capital Strength: An $8.9B take‑private by TowerBrook and CD&R is framed as providing resources for innovation and expansion. The transaction is described as validating market standing and future growth potential.

Strong Market Position & Advantage: The company is positioned as a leading platform in supplemental benefits and healthcare-fintech administration, with large managed-care penetration and national-scale benefit card acceptance. High-profile launches and reported platform scale (covered lives, transactions, annual spend) reinforce competitive standing within a concentrated field.

Strategic Partnerships: Major retail and ecosystem partnerships with Walmart, Walgreens, Dollar General, Instacart, and large grocery banners expand where and how members can use benefits. These integrations strengthen distribution, improve point-of-sale usability, and support ongoing volume growth.

Investor Backing & Capital Strength: Material growth financing and a significant investment led by General Atlantic indicate strong institutional support to scale operations and technology. This capital backing aligns with continued expansion via acquisitions and broader platform buildout.

Investor Backing & Capital Strength: Backers and funding announcements point to a strong capital base, including major investors (e.g., Carlyle, Patient Square) and substantial financing raised. Technology upgrade spend and continued sponsor support indicate capacity to sustain growth investments.

Market Expansion: Global moves and acquisitions show widening reach, with operations across 10+ locations and targeted expansion into the GCC via a strategic investment in Santechture. Add-on deals like Xtend Healthcare increased end-to-end RCM breadth and scale.

Innovation-Driven Growth: AI-powered platforms (e.g., PULSE, VISION) and clinically led analytics are highlighted as growth engines delivering material financial impact for client health systems. Recent technology investments and product launches underpin a tech-forward trajectory.

Strong Market Position & Advantage: The company is repeatedly characterized as a global leader in RTSM/IRT with substantial operating scale, supporting 2,000+ studies across 90+ countries and 800+ active studies. This breadth and ability to handle complex, global trials provide a durable competitive edge.

Investor Backing & Capital Strength: The June 2024 acquisition by Arsenal Capital Partners supplies focused capital and sponsor support to accelerate expansion and innovation. This backing is presented as validation of market position and a catalyst for the next phase of growth.

Innovation-Driven Growth: Five generations of purpose-built RTSM platforms and the proprietary PULSE platform, including faster study builds in four weeks or less, indicate sustained product advancement. A 2025 brand refresh and continued tech investment underscore a roadmap aimed at pushing RTSM forward.